Wejse, C.Petersen, E.Kaleebu, P.Oliver, M.Craig, G.Corrah, T.Tientcheu, L.Antonio, M.Rao, M.McHugh, T.D.Sheikh, A.Zumla, A.Maeurer, M.Chakaya, J.Hoelscher, M.Ntoumi, F.Rustomjee, R.Vilaplana, C.Yeboah-Manu, D.Rasolofo, V.Munderi, P.Singh, N.Aklillu, E.Padayatchi, N.Macete, E.Kapata, N.Mulenga, M.Kibiki, G.Mfinanga, S.Nyirenda, T.Maboko, L.Garcia-Basteiro, A.Rakotosamimanana, N.Bates, M.Mwaba, P.Reither, K.Gagneux, S.Edwards, S.Mfinanga, E.Abdulla, S.Cardona, P.-JRussell, J.B.W.Gant, V.Noursadeghi, M.Elkington, P.Bonnet, M.Menendez, C.Dieye, T.N.Diarra, B.Maiga, A.Aseffa, A.Parida, S.Ippolito, G.Ramjee, G.Kaufmann, S.H.E.Churchyard, G.Steyn, A.Grobusch, M.Sanne, I.Martinson, N.Madansein, R.Wilkinson, R.J.Mayosi, B.Schito, M.Wallis, R.S.2018-09-132018-09-132015-08DOI: 10.1038/nrd4696http://ugspace.ug.edu.gh/handle/123456789/24123The treatment of tuberculosis is based on combinations of drugs that directly target Mycobacterium tuberculosis. A new global initiative is now focusing on a complementary approach of developing adjunct host-directed therapiesenTuberculosisMycobacterium tuberculosisantibioticdrug-resistantpharmacokineticimmune reconstitution inflammatory syndrome (IRIS)Other